Sexual transmission of an HIV-1 variant resistant to multiple reverse- transcriptase and protease inhibitors

New England Journal of Medicine

Volumn 339, Issue 5, 1998, Pages 307-311

  Hecht, Frederick M ^a   Grant, Robert M ^a,b   Petropoulos, Christos J ^c   Dillon, Beth ^d   Chesney, Margaret A ^e   Tian, Huan ^c   Hellmann, Nicholas S ^c   Bandrapalli, Nirmala I ^b   Digilio, Laura ^b   Branson, Bernard ^d   Kahn, James O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLADSTONE INSTITUTES   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, HORIZONTAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; SEXUAL BEHAVIOR;

EID: 0032581588     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199807303390504     Document Type: Article

References (30)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
2. McDonald CK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 1997;157:951-9.
3. Decks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997;277:145-53.
4. Imrie A, Beveridge A, Genn W, Vizard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine: Sydney Primary HIV Infection Study Group. J Infect Dis 1997; 175:1502-6.
5. Veenstra J, Schuurman R, Cornelissen M, et al. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis 1995;21:556-60.
6. Ippolito G, Del Poggio P, Arici C, et al. Transmission of zidovudine-resistant HIV during a bloody fight. JAMA 1994;272:433-4.
7. Angarano G, Monno L, Appice A, et al. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts. AIDS 1994;8:1013-4.
8. Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis 1994;169:411-5.
9. Erice A, Mayers DL, Strike DG, et al. Primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993; 328:1163-5.
10. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-91.
11. Kozal M, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2:753-9.
12. Lipshutz RJ, Morris D, Chee M, et al. Using oligonucleotide probe arrays to access genetic diversity. Biotechniques 1995;19:442-7.
13. Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SPA. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A 1994;91:5022-6.
14. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
15. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-80.
16. Learn GH Jr, Korber BTM, Foley B, Hahn BH, Wolinsky SM, Mullins JI. Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol 1996;70:5720-30.
17. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985;39:783-91.
18. Sanderson M. Confidence limits on phylogenies: the bootstrap revisited. Cladistics 1989;5:113-29.
19. Schinazi RF, Lloyd RM Jr, Nguyen M-H, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875-81.
20. Yamaguchi K, Byrn RA. Clinical isolates of HIV-1 contain few preexisting proteinase inhibitor resistance-conferring mutations. Biochim Biophys Acta 1995;1253:136-40.
21. Barrie KA, Perez EE, Lamers SL, et al. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology 1996;219:407-16.
22. Ives KJ, Jacobsen H, Galpin SA, et al. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J Antimicrob Chemother 1997;39:771-9.
23. Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997;71:6662-70.
24. Kaplan AH, Michael SF, Wehbie RS, et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A 1994;91:5597-601.
25. Gulnik SV, Suvorov LI, Liu B, et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995;34:9282-7.
26. Rayner MM, Cordova B, Jackson DA. Population dynamics studies of wild type and drug-resistant mutant HIV in mixed injections. Virology 1997;236:85-94.
27. Wahlberg J, Fiore J, Angarano G, Uhlen M, Albert J. Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants. J Infect Dis 1994;169:611-4.
28. Hecht F, Chesney M, Busch MP, et al. Treatment of primary HIV with AZT, 3TC, and indinavir. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998. abstract.
29. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998;339:33-9.
30. Pudney J, Oneta M, Mayer K, Seage G III, Anderson D. Pre-ejaculatory fluid as potential vector for sexual transmission of HIV-1. Lincet 1992;340:1470.